About Kezar Life Sciences
Kezar Life Sciences is a company based in San Francisco (United States) founded in 2015 by Christopher Kirk and John Fowler was acquired by Aurinia Pharmaceuticals in March 2026. Kezar Life Sciences has raised $78.37 million across 2 funding rounds from investors including Nasdaq, TD Securities and Aurinia Pharmaceuticals. The company has 55 employees as of December 31, 2024. Kezar Life Sciences offers products and services including Zetomipzomib. Kezar Life Sciences operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter San Francisco, United States
- Employees 55 as on 31 Dec, 2024
- Founders Christopher Kirk, John Fowler
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kezar Life Sciences, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$83.74 M (USD)17.8as on Dec 31, 2024
-
EBITDA
-$88.09 M (USD)15.43as on Dec 31, 2024
-
Total Equity Funding
$78.37 M (USD)
in 2 rounds
-
Latest Funding Round
$50 M (USD), Series B
Jul 21, 2017
-
Investors
Nasdaq
& 11 more
-
Employee Count
55
as on Dec 31, 2024
-
Acquired by
Aurinia Pharmaceuticals
(Mar 30, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Kezar Life Sciences
Kezar Life Sciences is a publicly listed company on the NASDAQ with ticker symbol KZR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Kezar Life Sciences
Kezar Life Sciences offers a comprehensive portfolio of products and services, including Zetomipzomib.
Targets proteins for treating autoimmune hepatitis via selective inhibition.
Funding Insights of Kezar Life Sciences
Kezar Life Sciences has successfully raised a total of $78.37M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kezar Life Sciences
Kezar Life Sciences has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Nasdaq, TD Securities and Aurinia Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life-sciences sectors are managed.
|
Locked | Locked | Locked | |
|
Chiesi Ventures is focused on venture capital for rare diseases.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on healthcare startups
|
Locked | Locked | Locked |
Investor details for Kezar Life Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kezar Life Sciences
Investment portfolio details for Kezar Life Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kezar Life Sciences
Detailed financials for Kezar Life Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kezar Life Sciences Comparisons
Peer comparison for Kezar Life Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kezar Life Sciences
Kezar Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Kezar Life Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kezar Life Sciences
Complete news archive for Kezar Life Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kezar Life Sciences
Kezar Life Sciences was founded in 2015.
Kezar Life Sciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
John Fowler is the current CEO of Kezar Life Sciences. They have also founded this company.
Kezar Life Sciences is a funded company, having raised a total of $78.37M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Kezar Life Sciences is 55.
Kezar Life Sciences was founded in 2015 and is headquartered in San Francisco, United States. Therapies are developed by the company to target protein homeostasis, focusing on autoimmune disorders and hematologic tumors. Master regulators of cellular function are harnessed to address multiple disease drivers through single targets. The pipeline features KZR-616 and KZR-261 for these indications. Operations center on biotech research and drug development in the pharmaceutical sector.
Kezar Life Sciences's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
Kezar Life Sciences offers Zetomipzomib.
Yes, Kezar Life Sciences is publicly traded on NASDAQ under the ticker symbol KZR.
Kezar Life Sciences has 12 investors. Key investors include Nasdaq, TD Securities, Aurinia Pharmaceuticals, Bay City Capital, and EcoR1.
The ticker symbol of Kezar Life Sciences is KZR on NASDAQ.